Polycystic kidney disease future or investigational therapies
|
Polycystic kidney disease Microchapters |
|
Differentiating Polycystic kidney disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polycystic kidney disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Polycystic kidney disease future or investigational therapies |
|
FDA on Polycystic kidney disease future or investigational therapies |
|
CDC on Polycystic kidney disease future or investigational therapies |
|
Polycystic kidney disease future or investigational therapies in the news |
|
Blogs on Polycystic kidney disease future or investigational therapies |
|
Risk calculators and risk factors for Polycystic kidney disease future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]
Clinical trials and possible future treatments
- It is known that a certain molecule known as cAMP is involved in the enlargement of kidney cysts in PKD kidneys.[1]
- Various studies on rodents have shown that a molecule, called vasopressin, increases levels of cAMP in the body. When mice with PKD were given a chemical that blocks vasopressin, there was an impressive decrease in kidney size and some preservation of kidney function.
- Similarly, when studied mice consumed excessive amounts of water (which decreases levels of vasopressin), a similar result was seen. It has therefore been suggested that consuming large amounts of water may possibly assist in the treatment of early stage PKD.[2][3]
- As humans do not always mimic rodents in clinical trials, it is currently not yet certain whether vasopressin inhibitors, such as water, will have corresponding results in humans, or what negative effects excessive water intake may have on the kidneys of individuals with PKD.
- Clinical trials are currently underway in this field.[4]
- It has also been suggested that treatment with medications inhibiting vasopressin may assist in the management of PKD and reduce the speed at which kidney cysts form and grow, delaying the onset of end stage renal failure.
- Clinical trials are currently underway in the testing of Tolvaptan, a U.S. Food and Drug Administration (FDA) approved medication which has not yet been approved for use in the treatment of PKD.[5]
References
- ↑ "cAMP Regulates Cell Proliferation and Cyst Formation in Autosomal Polycystic Kidney Disease Cells". Jasn.asnjournals.org. 2000-07-01. Retrieved 2012-02-16.
- ↑ http://www.pkdcharity.co.uk/PKD%20Charity%20Newsletter%20Spring%202008.pdf
- ↑ http://cjasn.asnjournals.org/content/4/6/1140.full.pdf
- ↑ "High Water Intake to Slow Progression of Polycystic Kidney Disease - Full Text View". ClinicalTrials.gov. Retrieved 2012-02-16.
- ↑ "Otsuka Maryland Research Institute, Inc. Granted Fast Track Designation For Tolvaptan In PKD". Medicalnewstoday.com. Retrieved 2012-02-16.